Sino Biopharmaceutical announced acquisition of the remaining 95% stake in LaNova Medicines for up to $951 million, consolidating its antibody-drug conjugate and bispecific antibody assets. LaNova's pipeline includes licensed therapies from collaborations with AstraZeneca and Merck, emphasizing PD-1×VEGF bispecific antibodies and ADCs targeting GPRC5D and CCR8. This acquisition highlights rapid growth and consolidation in China's biotech sector and increased domestic innovation in oncology biologics.